For the first time in its history, Medicare will begin paying for a class of medications that it was legally prohibited from covering on Wednesday. The Medicare GLP-1 Bridge, a short-term pilot program that runs through the end of 2027, sets beneficiaries’ monthly costs for medications like Wegovy and Zepbound at $50. Up until now, these drugs have cost well over $1,000 per month for those without private insurance or substantial financial resources.
This type of change in policy is not an accident. Decades before anyone had heard of Ozempic, Medicare Part D plans were expressly forbidden from paying for drugs prescribed for weight loss. That didn’t change until GLP-1 medications evolved from specialized diabetes treatments to a cultural phenomenon that changed everything from airline seat design to wedding dress shopping. Not to mention, they made Eli Lilly and Novo Nordisk two of the most valuable companies in the world.
It’s difficult to ignore the timing. The pilot launch coincides with growing concerns about both manufacturers’ ability to maintain blockbuster growth in a market that has, up until now, mostly been restricted to consumers paying cash or having employer-sponsored insurance that is sufficiently generous to cover it. Medicare, which has about 67 million enrollees, is a completely different kind of client. Investors don’t seem to think that’s a coincidence.
Health policy observers believe that pharmaceutical companies have been subtly working the angles for years, including funding patient advocacy groups, commissioning cost-effectiveness studies, and courting members of Congress, to convince people that obesity is a disease that needs to be treated rather than a lifestyle problem that can be overcome with willpower. No one on the record will attest to whether that persistent, low-volume pressure tipped the scales inside CMS. However, their interests are undoubtedly served by the result.
Naturally, CMS Administrator Dr. Mehmet Oz presented the program in a different light, referring to the treatments as “a major medical advancement” that too many elderly people were unable to afford. That’s also not incorrect. Mary Abrahamson, a 71-year-old resident of rural Washington, has been taking a compounded form of tirzepatide for two years. Despite seeing improvements in her energy and sleep apnea, even at a discounted rate, she still finds the monthly bill to be a financial burden. The administration publicly relies on stories like hers because they are true.
The cost to taxpayers is less talked about. Budget analysts have quietly criticized CMS for not disclosing projected costs for the demonstration, pointing out that GLP-1 medications aren’t inexpensive to dispense at scale, even at negotiated rates. According to a widely cited 2025 study, depending on uptake and cost, expanding Medicare coverage for anti-obesity drugs could increase federal spending by tens of billions of dollars over ten years.
Another noteworthy aspect of the program’s structure is that it is only in place for eighteen months, ending in December 2027. That could be a politically convenient way to claim credit for access without committing to the long-term bill, or it could be a cautious pilot intended to test demand and cost before any permanent expansion. Which is still unknown.
It is evident that the GLP-1 story is no longer primarily about a single medication. It concerns the speed at which a whole health system, including insurers, regulators, pharmaceutical companies, and now Medicare itself, has rearranged itself around a class of medicine that hardly existed in its current form five years ago. One of the most notable changes in American health policy in recent memory has been witnessing that unfold, and the Bridge program is not likely to be the final chapter.
